Antimicrobial peptide S100A12 (calgranulin C) inhibits growth, biofilm formation, pyoverdine secretion and suppresses type VI secretion system in Pseudomonas aeruginosa.
Antimicrobial peptides
Biofilm
Pseudomonas
Pyoverdine
S100A12
Type VI secretion System
Journal
Microbial pathogenesis
ISSN: 1096-1208
Titre abrégé: Microb Pathog
Pays: England
ID NLM: 8606191
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
24
12
2021
revised:
17
06
2022
accepted:
20
06
2022
pubmed:
27
6
2022
medline:
10
8
2022
entrez:
26
6
2022
Statut:
ppublish
Résumé
Pseudomonas aeruginosa is an opportunistic pathogen and is the major cause of corneal infections in India and worldwide. The increase in antimicrobial resistance among Pseudomonas has prompted rise in significant research to develop alternative therapeutics. Antimicrobial peptides (AMPs) are considered as potent alternatives to combat bacterial infections. In this study, we investigated the role of S100A12, a host defense peptide, against PAO1 and an ocular clinical isolate. Increased expression of S100A12 was observed in corneal tissues obtained from Pseudomonas keratitis patients by immunohistochemistry. S100A12 significantly inhibited growth of Pseudomonas in vitro as determined from colony forming units. Furthermore, recombinant S100A12 reduced the corneal opacity and the bacterial load in a mouse model of Pseudomonas keratitis. Transcriptome changes in PAO1 in response to S100A12 was investigated using RNA sequencing. The pathway analysis of transcriptome data revealed that S100A12 inhibits expression of genes involved in pyoverdine synthesis and biofilm formation. It also impedes several important pathways like redox, pyocyanin synthesis and type 6 secretion system (T6SS). The transcriptome data was further validated by checking the expression of several affected genes by quantitative PCR. Our study sheds light on how S100A12 impacts Pseudomonas and that it might have the potential to be used as therapeutic intervention in addition to antibiotics to combat infection in future.
Identifiants
pubmed: 35753599
pii: S0882-4010(22)00267-4
doi: 10.1016/j.micpath.2022.105654
pii:
doi:
Substances chimiques
Antimicrobial Peptides
0
Leukocyte L1 Antigen Complex
0
Oligopeptides
0
S100A12 Protein
0
Type VI Secretion Systems
0
pyoverdin
8062-00-8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
105654Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.